Coherus Biosciences Inc

NASDAQ:CHRS   1:45:43 PM EDT
17.17
-0.62 (-3.48%)
Products, Other Pre-Announcement

Junshi Biosciences And Coherus Announce U.S. FDA Breakthrough Therapy Designation Granted For Toripalimab

Published: 08/12/2021 12:18 GMT
Coherus Biosciences Inc (CHRS) - Junshi Biosciences and Coherus Announce U.S. FDA Breakthrough Therapy Designation Granted for Toripalimab for 1st Line Treatment of Nasopharyngeal Carcinoma.
Coherus - Junshi Expects to Complete Bla Submission for Toripalimab Plus Chemotherapy for 1st Line Npc Later This Quarter.
Coherus - Junshi Expects to Complete Bla Submission for Toripalimab Monotherapy for 2nd Or 3rd Line Npc Later This Quarter.